REM
185 results
1 - 100
Overview of Risk Evaluation and Mitigation Systems (REMS) - eculizumab
- tolvaptan
- mavacamten
- thalidomide
- bosentan
- ambrisentan
- pomalidomide
- alvimopan
- ISOtretinoin
- fenfluramine
- remdesivir
- vandetanib
- vigabatrin
- pegvaliase
- brodalumab
- zilucoplan
- metreleptin
- iptacopan
- miFEPRIStone
- remimazolam
- crovalimab
- elotuzumab
- inotersen
- lomitapide
- riociguat
- loxapine
- teduglutide
- esketamine
- denosumab
- calcium oxybate/magnesium oxybate/potassium oxybate/sodium oxybate
- alemtuzumab
- natalizumab
- ravulizumab
- OLANZapine
- sodium oxybate
- lenalidomide
- collagenase clostridium histolyticum
- phentermine/topiramate
- peginesatide
- panobinostat
- pexidartinib
- teclistamab
- levorphanol
- duvelisib
- daclizumab
- melphalan
- mycophenolate mofetil
- elranatamab
- talquetamab
- hydroxyurea
- ezogabine
- mipomersen
- parathyroid hormone
- nalbuphine
- secobarbital
- albiglutide
- brexanolone
- butorphanol
- fentaNYL (transdermal)
- meperidine
- oxyMORphone
- SUFentanil
- buprenorphine
- How to Use Davis's Drug Guide For Nurses
- HYDROmorphone
- methadone
- tapentadol
- buprenorphine/naloxone
- amobarbital
- codeine